News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
329,468 Results
Type
Article (19793)
Company Profile (140)
Press Release (309535)
Section
Business (105497)
Career Advice (874)
Deals (18518)
Drug Delivery (93)
Drug Development (50765)
Employer Resources (79)
FDA (7664)
Job Trends (7742)
News (185969)
Policy (17331)
Tag
Academia (729)
Alliances (27945)
Alzheimer's disease (584)
Approvals (7652)
Artificial intelligence (87)
Bankruptcy (171)
Best Places to Work (5545)
Biosimilars (71)
Breast cancer (81)
Cancer (710)
Cardiovascular disease (68)
Career advice (708)
Cell therapy (110)
Clinical research (42091)
Collaboration (275)
Compensation (92)
COVID-19 (1078)
C-suite (67)
Data (771)
Diabetes (111)
Diagnostics (1728)
Drug pricing (97)
Earnings (38359)
Employer resources (73)
Events (47914)
Executive appointments (256)
FDA (8010)
Funding (195)
Gene therapy (95)
GLP-1 (512)
Government (1807)
Healthcare (5875)
Infectious disease (1131)
Inflammatory bowel disease (72)
Interviews (115)
IPO (7318)
Job creations (2437)
Job search strategy (646)
Layoffs (258)
Legal (4094)
Lung cancer (109)
Lymphoma (67)
Manufacturing (148)
Medical device (1986)
Medtech (1989)
Mergers & acquisitions (11289)
Metabolic disorders (373)
Neuroscience (782)
NextGen Class of 2024 (2352)
Non-profit (913)
Northern California (767)
Obesity (238)
Opinion (178)
Patents (85)
People (33036)
Pharmaceutical (78)
Phase I (13146)
Phase II (17815)
Phase III (14327)
Pipeline (322)
Policy (74)
Postmarket research (1616)
Preclinical (4603)
Radiopharmaceuticals (156)
Rare diseases (167)
Real estate (3168)
Regulatory (12235)
Research institute (816)
Resumes & cover letters (138)
Southern California (702)
Startups (2007)
United States (7006)
Vaccines (216)
Weight loss (201)
Date
Last 7 days (79)
Last 30 days (848)
Last 365 days (17332)
2025 (46)
2024 (17718)
2023 (19672)
2022 (25897)
2021 (26679)
2020 (24920)
2019 (20103)
2018 (15617)
2017 (17303)
2016 (16253)
2015 (18864)
2014 (14854)
2013 (12587)
2012 (13504)
2011 (13833)
2010 (12761)
Location
Africa (407)
Asia (24608)
Australia (3164)
California (1739)
Canada (844)
China (195)
Colorado (72)
Connecticut (69)
Europe (50797)
Florida (262)
Illinois (179)
Indiana (129)
Japan (69)
Maryland (258)
Massachusetts (1446)
Minnesota (100)
New Jersey (687)
New York (500)
North Carolina (378)
Northern California (767)
Ohio (65)
Pennsylvania (417)
South America (605)
Southern California (702)
Texas (238)
Washington State (160)
329,468 Results for "pact pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.
January 2, 2025
·
2 min read
·
Nick Paul Taylor
Collaboration
Merck Hops Onto PD-1/VEGF Train, Committing up to $3B Plus in LaNova Deal
Despite recent enthusiasm around the PD-1/VEGF space, BMO Capital Markets analyst Evan Seigerman noted that Merck’s pact with LaNova Medicines is more “conservativism” on the pharma’s part than confirmatory of recent data in the drug class.
November 14, 2024
·
2 min read
·
Tristan Manalac
Cancer
Kura Signs Leukemia Pact with Kyowa Kirin After Losing Race to Syndax
The agreement will give Kura enough capital to support the development and launch of its menin inhibitor ziftomenib.
November 21, 2024
·
2 min read
·
Tristan Manalac
GLP-1
Obesity Startup Metsera Inks Manufacturing Pact With Amneal on Heels of Phase I Readout
A week after it released positive early-stage data, Metsera has partnered with Amneal Pharmaceuticals in an effort to secure the development and supply of its investigational weight loss therapy MET-097.
October 1, 2024
·
2 min read
·
Tristan Manalac
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Deals
Two Private Equity Firms Near Potential $3B+ Deal for Mitsubishi’s Pharma Unit: Reuters
Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.
December 13, 2024
·
1 min read
·
Annalee Armstrong
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Business
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.
November 27, 2024
·
9 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
1 of 32,947
Next
